Retatrutide is a novel, long-acting GLP-1 receptor agonist primarily used to treat type 2 diabetes and obesity. It mimics the effects of the intestinal hormone GLP-1, delaying gastric emptying, enhancing satiety, and promoting insulin secretion, thereby helping to control blood sugar and reduce weight. Use requires strict medical supervision and is contraindicated in patients with a history of pancreatitis or medullary thyroid cancer.
Indications and Mechanism of Action
Type 2 Diabetes: Used as an adjunct to diet and exercise to improve glycemic control. It can lower glycated hemoglobin (HbA1c) when used alone or in combination with other glucose-lowering medications. 1.
Obesity or Overweight Management: Suitable for patients with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² and obesity-related complications, combined with lifestyle interventions. 2.
Cardiovascular Protection: Some studies suggest it may reduce the risk of cardiovascular events, but further clinical evidence is needed.
